NCT00035581 - Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions

HIV SeropositivityHIV Infection

Interventions

DRUG

poly I-poly C12U

200-400 mg IV infusions 2x/week for 24 weeks

Trial Locations (7)

W. Chris Woodward, DO, Reading

Dupont Circle Physicians Group, Washington D.C.

Julia Torres, MD, Fort Lauderdale

Scott Ubillos, MD, Tampa

Orange County Center for Special Immunology, Fountain Valley

Circle Medical Center, Norwalk

St. Michael's Medical Center, Newark